NIH NOTICES

Notice of Intent to Publish the Reissuance of RFA-OD-18-002 "Tobacco Regulatory Science (R01 Clinical Trial Optional)" (NOT-OD-19-062)
National Cancer Institute

Notice of a Pre-Application Webinar for RFA-CA-19-007 and RFA-CA-19-008 on the Experimental Therapeutics Clinical Trials Network (ETCTN) (UM1) and ETCTN Pharmacokinetic Resource Laboratories (U24), respectively (NOT-CA-19-021)
National Cancer Institute

Notice of Information: Updates and clarifications of several components of the Challenge competition posted within the Federal Register (NOT-OD-19-046)
National Institutes of Health

National Institutes of Health

Notice of Clarification Regarding Harassment and Discrimination Protections in NIH Training Applications (NOT-OD-19-056)
National Institutes of Health

Extension of Comment Period on Draft Report: Reducing Administrative Burden to Researchers for Animal Care and Use in Research (NOT-OD-19-057)
National Institutes of Health

Register to Attend the NIH Regional Seminar on Program Funding and Grants Administration Baltimore, MD May 2019 (NOT-OD-19-058)
National Institutes of Health

Notice of Added Receipt Dates and Later Expiration Date for PA-19-029, Innovation Corps (I-Corps) at NIH Program for NIH and CDC Translational Research (Admin Supp Clinical Trial Not Allowed) (NOT-CA-19-017)
National Cancer Institute

Pre-Application Webinar for RFA-CA-19-033, Improving Outcomes for Pediatric, Adolescent and Young Adult Cancer Survivors (U01 Clinical Trial Required) (NOT-CA-19-020)
National Cancer Institute

Notice of Request for Information to Better Facilitate Cancer Systems Epidemiology Research (NOT-CA-19-019)
National Cancer Institute

Notice for a Pre-application Webinar for Funding Opportunity Announcement PAR-18-947 "Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)" (NOT-CA-19-023)
National Cancer Institute

Notice of Change to Award Information in RFA-CA-19-032 "Provocative Questions (PQs) in Cancer with an Underlying HIV Infection (R01 Clinical Trial Optional)" (NOT-CA-19-024)
National Cancer Institute
FEBRUARY DEADLINES

Foundation and Other Sources

American Society for Radiation Oncology
ASTRO-BCRF Career Development Award to End Cancer
**Deadline:** 2/15/2019
[https://www.astro.org/Patient-Care-and-Research/Research/Funding-Opportunities/ASTRO-BCRF-Award](https://www.astro.org/Patient-Care-and-Research/Research/Funding-Opportunities/ASTRO-BCRF-Award)

**About:** The goal of this award is to advance the field of radiation oncology in novel ways through the support of talented early-career scientists performing radiation-oncology related research. The aim is to support the next generation of researchers and to significantly improve outcomes and quality of life for breast cancer patients.  
**Period of Support:** 2 years  
**Funds/Direct Costs:** $100,000 direct costs per year

**Program Contact:** Scientific Affairs Department  
research@astro.org

NEW

LUNGevity Foundation
Career Development Award
**Letter of Intent Deadline:** 2/19/2019  
**Full Application Deadline:** 5/3/2019

**About:** LUNGevity’s Career Development Awards for Translational Research program was created to support future research leaders who will keep the field of lung cancer research vibrant with new ideas. Applicants must be within the first 5 years of their faculty appointment. Projects that will be funded in 2019 are expected to have a direct impact on the early detection of lung cancer or on the outcomes of lung cancer, or to provide a clear conceptual or experimental foundation for the future development of methods for early detection and/or individualized treatment, including through targeted therapy and immunotherapy.

**Period of Support:** 3 years  
**Funds/Direct Costs:** Direct costs are limited to $100,000 per year

**Program Contact:** Margery Jacobson  
(312) 407-6109  
mjacobson@LUNGevity.org

Conquer Cancer Foundation of ASCO
Endowed Young Investigator Award (YIA) in Mantle Cell Lymphoma (MCL)
**Deadline:** 2/25/2019
[https://www.conquer.org/young-investigator-award-yia-mcl](https://www.conquer.org/young-investigator-award-yia-mcl)

**About:** The Conquer Cancer Foundation of ASCO Endowed Young Investigator Award (YIA) in Mantle Cell Lymphoma (MCL) provides funding to promising investigators to encourage and promote quality clinical research in MCL. The purpose of this award is to fund physicians during the transition from a fellowship program to a faculty appointment. The Conquer Cancer Foundation welcomes application submissions only from investigators who are committed to conducting clinical and translational MCL research.

**Period of Support:** 1 year  
**Funds/Direct Costs:** $50,000 total costs for entire period of support

**Program Contact:** Conquer Cancer Foundation of ASCO  
grants@conquer.org

Intramural Funding Opportunities

Massey Cancer Center  
Pilot Research Grant
**Deadline:** 2/20/2019
[https://massey.vcu.edu/research/funding/pilot-project-program/](https://massey.vcu.edu/research/funding/pilot-project-program/)

**About:** VCU Massey Cancer Center offers funding for pilot projects to encourage new collaborative cancer research projects. Massey research members and associate members are eligible to apply. The intent of these pilot projects is to provide initial funding for new, collaborative projects with significant involvement of at least two independent investigators. A major purpose of this program is to allow collaborative research teams the ability to gather preliminary data needed for the investigators to prepare a successful grant application for a larger study. All interested investigators are required to submit a Pre-Application Form prior to submitting a full application.

**Period of Support:** 1 year  
**Funds/Direct Costs:** Up to $50,000 for entire period of support

**Internal Contact:** Olivia Patterson  
(804) 628-1931  
opatterson@vcu.edu

Program Announcements (PA)

National Cancer Institute  
Leveraging Population-based Cancer Registry Data to Study Health Disparities (R21)
**Deadline:** 02/16/2019

**About:** The goal of this Funding Opportunity Announcement (FOA) is to efficiently use the existing cancer registry infrastructure by augmenting data already collected with additional information needed to understand health disparities among people diagnosed with cancer.
Period of Support: Up to 2 years
Funds/Direct Costs: The combined budget for direct costs for the two-year project period may not exceed $275,000
Program Contact: Kathleen Cronin
(240) 276-6836
cronink@mail.nih.gov

National Cancer Institute
Integration of Individual Residential Histories into Cancer Research (R01)
Deadline: 02/05/2019
About: The purpose of this Funding Opportunity Announcement (FOA) is to support substantive investigation of the role of individual residential histories in cancer etiology and outcomes, and to encourage the development of complex analytical strategies in support of substantive investigation.

Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Zaria Tatalovich
(240) 276-6976
tatalovichzp@mail.nih.gov

National Cancer Institute
The Interplay of Cell Death Pathways in Cancer Cell Survival and Resistance to Therapy (R21)
Deadline: 02/16/2019
About: The purpose of this funding opportunity announcement (FOA) is to stimulate research in the interplay between cell death pathways in naïve and drug resistant cancers.

Period of Support: Up to 2 years
Funds/Direct Costs: $275,000 direct costs for entire period of support
Program Contact: Konstantin Salnikow
(240) 276-6230
salnikok@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
Biology of Lung, and Head and Neck Preneoplasias (R21 - Clinical Trial Not Allowed)
Deadline: 02/16/2019
About: This Funding Opportunity Announcement (FOA) seeks applications investigating mechanistic and biological aspects of preneoplasia leading to lung, and head and neck (HN) cancers. Despite improved therapies and a deeper molecular understanding of lung and HN cancers, these tumors remain a major health problem in the United States and globally.

Period of Support: Up to 2 years
Funds/Direct Costs: Application budgets are limited to $275,000 in direct costs per year
Program Contact: Erica S. Breslau
(240) 276-6773
breslaue@mail.nih.gov

National Cancer Institute
Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery (R21 Clinical Trial Optional)
Deadline: 02/16/2019
About: The purpose of this funding opportunity announcement (FOA) is to encourage exploratory/developmental research grant applications to: (1) assess and describe the current state of oral anticancer medication utilization, delivery, and adherence; (2) identify structural, systemic, and psychosocial barriers to adherence; and (3) develop models and strategies to improve safe and effective delivery of these agents so that clinical outcomes are optimized.

Period of Support: Up to 2 years
Funds/Direct Costs: The combined budget for direct costs for the two-year project period may not exceed $275,000.
Program Contact: Wendy Nelson
(240) 276-6971
nelsonw@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
Reducing Overscreening for Breast, Cervical, and Colorectal Cancers among Older Adults (R21 Clinical Trial Optional)
Deadline: 02/16/2019
About: The purpose of this Funding Opportunity Announcement (FOA) is to promote research on interventions, based in healthcare settings, designed to reduce overscreening for breast, cervical, or colorectal cancers among average-risk older adults.

Period of Support: Up to 2 years
Funds/Direct Costs: The combined budget for direct costs for the two-year project period may not exceed $275,000.
Program Contact: Long Nguyen
(240) 276-5807
long.nguyen@nih.gov
Multiple Institutes, including the National Cancer Institute
Advancing the Science of Geriatric Palliative Care (R21 - Clinical Trial Optional)
**Deadline:** 02/16/2019

**About:** This Funding Opportunity Announcement (FOA) encourages exploratory or developmental research grant applications to develop new tools, methods, and models focused on palliative care in geriatric populations.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** The combined budget for direct costs for the two-year project period may not exceed $275,000.

**Program Contact:** Ann M. O'Mara
(240) 276-7050
omaraa@mail.nih.gov

---

National Cancer Institute
Early-life Factors and Cancer Development Later in Life (R01)
**Deadline:** 02/05/2019

**About:** The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research focused on the role of early-life factors (maternal-paternal, in utero, birth and infancy, puberty, adolescence, and young adult years) in cancer development later in life.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Somdat Mahabir
(240) 276-6941
mahabir@mail.nih.gov

---

National Cancer Institute
Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)
**Deadline:** 02/05/2019

**About:** Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are limited to $499,999 (maximum) in direct costs per year

**Program Contact:** Anne Menkens
(240) 276-6510
menkensa@mail.nih.gov

---

Multiple Institutes, including the National Cancer Institute
Exploratory/Developmental Clinical Research Grants in Obesity (R21 Clinical Trial Optional)
**Deadline:** 02/16/2019

**About:** This Funding Opportunity Announcement (FOA) encourages research grant applications from institutions/organizations that propose to conduct exploratory/developmental clinical studies that will accelerate the development of effective interventions for prevention or treatment of overweight or obesity in adults and/or children.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** Application budgets are limited to $275,000 in direct costs per year.

**Program Contact:** Tanya Agurs-Collins
(240) 276-6956
collinsta@mail.nih.gov

---

Multiple Institutes, including the National Cancer Institute
Biobehavioral Basis of Chronic Pain (R21 Clinical Trial Optional)
**Deadline:** 02/16/2019

**About:** The purpose of the Funding Opportunity Announcement is to encourage grant applications from the scientific community on the biobehavioral basis of chronic pain. The focus encompasses the individual phenotype, genotype, and other omic-type assessments and the associated sensory and emotional components that
underpin the individual’s chronic pain experience.

**Period of Support:** 2 years

**Funds/Direct Costs:** $275,000 direct costs for entire period of support

**Program Contact:**
(240) 276-6291
hines@mail.nih.gov

---

**National Cancer Institute**
**NCI Transition Career Development Award to Promote Diversity (K22 No Independent Clinical Trials)**

**Deadline:** 02/12/2019


**About:** The purpose of the NCI Transition Career Development Award to Promote Diversity is to assist postdoctoral fellows or individuals in equivalent positions to transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist.

**Period of Support:** Up to 3 years

**Funds/Direct Costs:** Award budgets are composed of salary and other program-related expenses, as described in announcement.

**Program Contact:**
Abigail Soyombo
(240) 276-6553
Abigail.Soyombo@nih.gov

---

**Multiple Institutes, including the National Cancer Institute**
**Biobehavioral Basis of Chronic Pain (R01 Clinical Trial Optional)**

**Deadline:** 2/5/2019


**About:** The purpose of the Funding Opportunity Announcement is to encourage grant applications from the scientific community on the biobehavioral basis of chronic pain. The focus encompasses the individual phenotype, genotype, and other omic-type assessments and the associated sensory and emotional components that underpin the individual’s chronic pain experience.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:**
Ann O’Mara
(240) 276-7050
omaraa@mail.nih.gov

---

**National Cancer Institute**
**Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)**

**Deadline:** 02/11/2019


**About:** This Funding Opportunity Announcement (FOA) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and clinical data.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** The combined budget for direct costs for the entire project period may not exceed $275,000.

**Program Contact:**
Nonniekaye Shelburne
(240) 276-6897
nshelburne@mail.nih.gov

---

**National Cancer Institute**
**Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R21)**

**Deadline:** 02/16/2019


**About:** This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to mitigate cardiovascular dysfunction while optimizing cancer outcomes.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** The combined budget for direct costs for the entire project period may not exceed $275,000.

**Program Contact:**
Claire Zhu
(240) 276-7013
zhucla@mail.nih.gov

---

**Multiple Institutes, including the National Cancer Institute**
**Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed)**

**Deadline:** 02/12/2019


**About:** The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Award budgets are composed of salary and other program-related expenses, as described in announcement.

**Program Contact:**
Claire Zhu
(240) 276-7013
zhucla@mail.nih.gov

---

**Multiple Institutes, including the National Cancer Institute**
**NCI Transition Career Development Award to Promote Diversity (K22 No Independent Clinical Trials)**

**Deadline:** 02/12/2019

and other program-related expenses, as described in announcement.

Program Contact: Susan Lim  
(240) 276-5588  
lims@mail.nih.gov

Multiple Institutes, including the National Cancer Institute

Administrative Supplement for Research on Sex/Gender Influences (Admin Supp Clinical Trial Optional)

Deadline: 2/20/2019  

About: The Office of Research on Women's Health (ORWH) announces the availability of administrative supplements to support research highlighting the impact of sex/gender influences in human health and illness, including basic, preclinical, clinical, translational, and behavioral studies. Of special interest are studies relevant to understanding the significance of biological sex on cells and tissue explants; comparative studies of male and female tissues, organ systems and physiological systems; sex-based comparisons of pathophysiology, biomarkers, gene expression, clinical presentation and prevention and treatment of diseases.

Period of Support: 1 year

Funds/Direct Costs: Application budget cannot exceed a maximum direct cost of $100,000 excluding consortium F&A costs. In addition to the direct cost, applicable F&A (indirect) cost can also be requested.

Program Contact: Crystal Wolfrey  
(240) 276-6277  
wolfreycc@mail.nih.gov

National Cancer Institute

Neural Regulation of Cancer (R01)

Deadline: 02/22/2019  

About: This Funding Opportunity Announcement (FOA) encourages collaborative, transdisciplinary research with both neuroscience and cancer elements, which together will advance current understanding of the nervous system contribution to cancer.

Period of Support: Up to 5 years

Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.

Program Contact: Chamelli Jhappan  
(240) 276-6200  
jhappanc@mail.nih.gov

Cancer-Related Behavioral Research through Integrating Existing Data (R01)

Deadline: 02/05/2019  

About: This Funding Opportunity Announcement (FOA) invites applications that seek to integrate two or more independent data sets to answer novel cancer control and prevention questions. The goal is to encourage applications that incorporate Integrative Data Analysis (IDA) methods to study behavioral risk factors for cancer, including tobacco use, sedentary behavior, poor weight management, and lack of medical adherence to screening and vaccine uptake.

Period of Support: Up to 5 years

Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.

Program Contact: Richard P. Moser  
(240) 276-6915  
moserr@mail.nih.gov

Multiple Institutes, including the National Cancer Institute

Traceback Testing: Increasing Identification and Genetic Counseling of Mutation Carriers through Family-based Outreach (U01 Clinical Trial Optional)

Deadline: 02/05/2019  

About: The purpose of the Funding Opportunity Announcement (FOA) is to support pilot research projects using a "Traceback" approach to genetic testing women with a personal or family history of ovarian cancer and reaching out to family members to identify unaffected individuals at increased risk for cancer in different clinical contexts and communities, including racially/ethnically diverse populations.

Period of Support: Up to 4 years

Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.

Program Contact: Goli Samimi  
(301) 276-6582  
golisamimi@nih.gov

Multiple Institutes, including the National Cancer Institute

Time-Sensitive Obesity Policy and Program Evaluation (R01 Clinical Trial Not Allowed)

Deadline: 02/11/2019  

About: This Funding Opportunity Announcement (FOA) invites applications that seek to integrate two or more independent data sets to answer novel cancer control and prevention questions. The goal is to encourage applications that incorporate Integrative Data Analysis (IDA) methods to study behavioral risk factors for cancer, including tobacco use, sedentary behavior, poor weight management, and lack of medical adherence to screening and vaccine uptake.

Period of Support: Up to 5 years

Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: David Berrigan  
(240) 276-6752  
berrigand@mail.nih.gov

---

**National Cancer Institute**  
**Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)**  
**Deadline:** 02/13/2019  
**About:** The purpose of this Funding Opportunity Announcement (FOA) is to support the validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control.  
**Period of Support:** Up to 3 years  
**Funds/Direct Costs:** Applicants may request up to $275,000 direct costs for the entire UH2 phase with no more than $200,000 requested in any one year and up to $250,000 direct costs for the UH3 phase per year.  
**Program Contact:** Tracy G. Lively  
(240) 276-5944  
livelyt@mail.nih.gov

---

**National Cancer Institute**  
**Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R21)**  
**Deadline:** 02/16/2019  
**About:** This Funding Opportunity Announcement (FOA) encourages transdisciplinary and translational research that will identify the specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival. Research applications should test the effects of physical activity, alone or in combination with weight control (either weight loss or avoidance of weight gain), on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other than insulin/glucose metabolism, especially those obtained from tumor tissue sourced from repeat biopsies where available.  
**Period of Support:** 2 years  
**Funds/Direct Costs:** $275,000 direct costs for entire period of support  
**Program Contact:** Frank Perna  
(240) 276-6782  
pernafm@mail.nih.gov

---

**Multiple Institutes, including the National Cancer Institute**  
**Diet and Physical Activity Assessment Methodology (R21 Clinical Trial Not Allowed)**  
**Deadline:** 02/16/2019  
**About:** This Funding Opportunity Announcement (FOA) encourages innovative research to enhance the quality of measurements of dietary intake and physical activity.  
**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** Direct costs are limited to $275,000 per year  
**Program Contact:** Carol Perry  
(240) 276-6282  
perryc@nci.nih.gov

---

**Multiple Institutes, including the National Cancer Institute**  
**Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)**  
**Deadline:** 02/08/2019  
**About:** This Funding Opportunity Announcement (FOA) will support pilot, feasibility or exploratory research in 5 priority areas in substance use epidemiology and health services, including: 1) responses to sudden and severe emerging drug issues 2) responses to emerging marijuana trends and topics related to the shifting policy landscape; 3) responses to unexpected and time-sensitive prescription drug abuse research opportunities 4) responses to unexpected and time-sensitive medical system issues; and 5) responses to unexpected and time-sensitive criminal or juvenile justice that relate to drug abuse and access and provision of health care service.  
**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** Direct costs are limited to $275,000  
**Program Contact:** Kelly D. Blake  
(240) 281-5934  
kelly.blake@nih.gov

---

**Multiple Institutes, including the National Cancer Institute**  
**End-of-Life and Palliative Care Approaches to Advanced Signs and Symptoms (R21)**  
**Deadline:** 02/16/2019  
**About:** The purpose of this funding opportunity announcement (FOA) is to stimulate research to examine the multi-dimensional foundations, experiences and management of complex, advanced signs and symptoms at the end of life.  
**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** $275,000 direct costs for entire period of support
Program Contact: Karen Kehl  
(301) 594-8010  
kehlka@nih.gov

Multiple Institutes, including the National Cancer Institute
Advancing the Science of Geriatric Palliative Care (R21 - Clinical Trial Optional)
Deadline: 02/16/2019

About: This Funding Opportunity Announcement (FOA) encourages exploratory or developmental research grant applications to develop new tools, methods, and models focused on palliative care in geriatric populations. This FOA covers studies in a variety of settings including hospitals (and specific sites within hospitals including specialty medical or surgical wards, intensive care units, and emergency departments), post-acute care settings, outpatient clinics and doctors' offices, patients' homes and other residential settings, assisted living facilities, nursing homes, hospices, and other healthcare or community settings.

Period of Support: Up to 2 years
Funds/Direct Costs: The combined budget for direct costs for the two-year project period may not exceed $275,000.
Program Contact: Ann M. O'Mara  
(240) 276-7050  
omaraa@mail.nih.gov

National Cancer Institute
Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)
Deadline: 02/16/2019

About: The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.

Period of Support: Up to 2 years
Funds/Direct Costs: Application budgets are limited to $275,000 in direct costs per year
Program Contact: Miguel R. Ossandon  
(240) 276-5714  
ossandom@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed)
Deadline: 02/16/2019

About: This FOA will support activities proposing to conduct analyses of existing ABCD Study data to accelerate the pace of research on child health and development, including: cross-sectional and/or longitudinal analyses; development of new or advanced statistical methods; and/or integration of multiple data sets with common data elements. Existing data provide unique opportunities to answer novel research questions in a cost-effective way. We also strongly encourage inclusion of statisticians, computational neuroscientists, and interdisciplinary teams to address novel research questions using these data.

Period of Support: Up to 2 years
Funds/Direct Costs: The combined budget for direct costs for the two-year project period may not exceed $275,000.
Program Contact: Crystal Wolfrey  
(240) 276-6277  
wolfreyc@mail.nih.gov

National Cancer Institute
Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R01 Clinical Trial Required)
Deadline: 02/14/2019

About: This Funding Opportunity Announcement (FOA) is intended to support clinical trials conducting preliminary
evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided planning and/or execution therapy, contrast kinetic modeling, 3-D reconstruction and other quantitative tools.

**Period of Support:** Up to 3 years

**Funds/Direct Costs:** Application budgets are limited to $500,000 in direct costs per year.

**Program Contact:** Lori A. Henderson
(240) 276-5930
hendersonlori@mail.nih.gov

---

**Multiple Institutes, including the National Cancer Institute**

**Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)**

**Deadline:** 2/16/2019


**About:** This Funding Opportunity Announcement (FOA) encourages investigators to submit research grant applications that will identify, develop, test, evaluate and/or refine strategies to disseminate and implement evidence-based practices (e.g. behavioral interventions; prevention, early detection, diagnostic, treatment and disease management interventions; quality improvement programs) into public health, clinical practice, and community settings. In addition, studies to advance dissemination and implementation research methods and measures are encouraged.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** The combined budget for direct costs for the two-year project period may not exceed $275,000.

**Program Contact:** Crystal Wolfrey
(240) 276-6277
wolfreyc@mail.nih.gov

---

**National Cancer Institute**

**NCI Small Grants Program for Cancer Research (NCI Omnibus R03 Clinical Trial Optional)**

**Deadline:** 02/26/2019


**About:** This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** A budget for direct costs of up to $50,000 per year may be requested.

**Program Contact:** Crystal Wolfrey
(240) 276-6277
wolfreyc@mail.nih.gov

---

**National Cancer Institute**

**NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)**

**Deadline:** 2/20/2019


**About:** This Funding Opportunity Announcement (FOA) supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies--including the use of new clinically-relevant models and imaging technologies--which could lead to first-in-human clinical trials.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** The combined budget for direct costs for the two-year project period may not exceed $275,000.

**Program Contact:** William C. Timmer
(240) 276-6130
william.timmer@nih.gov
National Cancer Institute

Immuno-Oncology Translation Network (IOTN): Cancer
Immunoprevention Research Projects (UG3/UH3)

**Deadline:** 2/11/2019

**About:** The goal of this FOA is to foster collaborative team science approaches to accelerate the discovery of new immune targets and evaluate novel immune-based therapies and combination approaches that eliminate established cancers in adults or to prevent cancers before they occur. The purpose of this FOA is to support UG3/UH3 phased award Projects as part of the expanded Immuno-Oncology Translational Network (IOTN).

**Period of Support:** Up to 3 years
**Funds/Direct Costs:** Up to $500,000 direct costs per year for both the UG3 phase and the UH3 phase

**Program Contact:** Robert Shoemaker  
(240) 276-7077  
shoemakr@mail.nih.gov

---

National Cancer Institute

NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 Independent Clinical Trial Not Allowed)

**Deadline:** 2/26/2019  

**About:** The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Fellows (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions.

**Period of Support:** Up to 5 years
**Funds/Direct Costs:** Award budgets are composed of salary and other program-related expenses, as described in announcement.

**Program Contact:** Michele McGuirl, PhD  
(240) 276-5421  
mcguirlm@mail.nih.gov

---

National Cancer Institute

Implementation Science for Cancer Control: Developing Centers (P50 Clinical Trial Optional)

**Deadline:** 2/11/2019

**About:** The purpose of this FOA is to support P50 Developing Centers that will build research capacity to study high priority areas of cancer control implementation science, build implementation laboratories, improve the state of measurement and methods, and improve the adoption, implementation, and sustainment of evidence-based cancer control interventions. Specifically, this FOA targets the following areas designated as scientific priorities by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based Approaches; Symptom Management, Prevention and Screening: High-Risk Cancers and other cross-cutting Moonshot priorities.

**Period of Support:** Up to 5 years
**Funds/Direct Costs:** Budget is limited to $600,000 in direct costs per year.

**Program Contact:** April Oh  
(240) 276-6709  
ohay@mail.nih.gov

---

National Cancer Institute

Accelerating Colorectal Cancer Screening and follow-up through Implementation Science (ACCSIS, Second Wave) (UG3/UH3)

**Deadline:** 2/11/2019  

**About:** The purpose of this FOA is to promote research in colorectal cancer (CRC) screening, follow-up, and referral-to-care in regions of the United States (U.S.) where screening rates are below national standards. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based approaches.

**Period of Support:** Up to 5 years
**Funds/Direct Costs:** Up to $500,000 in direct costs per year for UG3, $800,000 in direct costs per year for UH3

**Program Contact:** Sarah Kobrin  
(240) 276-6931  
sarah.kobrin@nih.gov

---

Multiple Institutes, including the National Cancer Institute

Tobacco Regulatory Science Small Grant Program for New Investigators (R03 Clinical Trial Optional)

**Deadline:** 2/13/2019  

**About:** The purpose of this Funding Opportunity Announcement (FOA) is to support New Investigators in the biomedical, behavioral, and social sciences who are in the early stages of establishing independent careers in tobacco regulatory research. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-
contained research projects; development of research methodology; and development of new research technology.

**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** Application budgets are limited to $50,000 in direct cost per year  
**Program Contact:** Rachel Grana Mayne  
(240) 276-5899  
granar@nih.gov

---

**Multiple Institutes, including the National Cancer Institute**  
**Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R21 Clinical Trial Not Allowed)**  
**Deadline:** 02/11/2019  
**About:** This R21 NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of pain target discovery and validation projects. These studies may involve considerable risk but may lead to a breakthrough in a pain treatment.  
**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** The combined budget for direct costs for the two-year project period may not exceed $275,000.  
**Program Contact:** Ann O'Mara  
(240) 276-7050  
omaraa@mail.nih.gov

---

**Multiple Institutes, including the National Cancer Institute**  
**Immuno-Oncology Translation Network (IOTN): Immuno-engineering to Improve Immunotherapy (i3) Centers (U54)**  
**Deadline:** 2/11/2019  
**About:** The purpose of this FOA is to develop Immuno-engineering to Improve Immunotherapy (i3) Centers, as new components of the Immuno-Oncology Translation Network (IOTN). The i3 Centers will be comprised of multi-disciplinary teams focused on developing and employing engineered immunotherapy approaches to design more durable, widely accessible, and less toxic immunoprevention and immunotherapy strategies.  
**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Up to $900,000 in direct costs per year  
**Program Contact:** Kevin Howcroft  
(240) 276-6702  
howcroftk@mail.nih.gov

---

**National Cancer Institute**  
**Immuno-Oncology Translation Network (IOTN): Cancer Immunotherapy Research Projects (U01)**  
**Deadline:** 2/8/2019  
**About:** The purpose of this FOA is to expand organ site-specific Cancer Immunotherapy Research Projects as components of the Immuno-Oncology Translation Network (IOTN). The IOTN will form an integrated network of multi-disciplinary, collaborative teams with the overarching goals of accelerating translational research of innate and adaptive immune mechanisms that contribute to tumor progression, and evaluating new or improved immunotherapeutic strategies (including combinations with standard or other therapies) that result in durable anti-cancer responses.  
**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Each application budget is limited to $500,000 in direct costs per year.  
**Program Contact:** Nancy Boudreau  
(240) 276-6702  
nancy.boudreau@nih.gov

---

**Multiple Institutes, including the National Cancer Institute**  
**Tobacco Regulatory Science (R21 Clinical Trial Optional)**  
**Deadline:** 2/13/2019  
**About:** The purpose of this Funding Opportunity Announcement (FOA) is to invite research project applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP).  
**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** The combined budget for direct costs for the entire project period may not exceed $275,000.  
**Program Contact:** Carol Perry  
(301) 613-5228  
perryc@nih.gov

---

**MARCH/APRIL DEADLINES**

**Foundation and Other Sources**

**NEW**  
**Department of Defense**  
**Breast Cancer Research Program (BCRP) Breakthrough Award**  
**Letter of Intent Deadline:** 3/14/2019  
**Full Application Deadline:** 3/28/2019  
**About:** Applications to the Fiscal Year 2019 (FY19) Breast Cancer Research Program (BCRP) are being solicited for the...
Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358). The BCRP challenges the scientific community to design research that will address the urgency of ending breast cancer. Specifically, the BCRP seeks to accelerate high-impact research with clinical relevance, encourage innovation and stimulate creativity, and facilitate productive collaborations.

**Period of Support**: 3-5 years depending on funding level  
**Funds/Direct Costs**: See announcement for details.  
**Program Contact**: Congressionally Directed Medical Research Program  
(301) 682-5507  
help@eBRAP.org

---

**NEW**  
**Department of Defense**  
**Breast Cancer Research Program (BCRP) Distinguished Investigator Award**  
**Letter of Intent Deadline**: 3/12/2019  
**Full Application Deadline**: 6/13/2019  
**About**: The BCRP Distinguished Investigator Award enables established visionary leaders from any field to pursue innovative ideas that could accelerate progress toward ending breast cancer. These individuals should be exceptionally talented researchers who have shown that they are leaders in their field(s) through extraordinary creativity, vision, and productivity.  
**Period of Support**: Up to 4 years  
**Funds/Direct Costs**: $3M direct costs for entire period of support  
**Program Contact**: Congressionally Directed Medical Research Program  
(301) 682-5507  
help@eBRAP.org

---

**NEW**  
**Department of Defense**  
**Breast Cancer Research Program (BCRP) Innovator Award**  
**Letter of Intent Deadline**: 3/12/2019  
**Full Application Deadline**: 6/13/2019  
**About**: The Innovator Award supports visionary individuals who have demonstrated exceptional creativity, innovative work, and paradigm-shifting leadership in any field including, but not limited to, breast cancer. The Innovator Award will provide these individuals with the funding and freedom to pursue their most novel, visionary, high-risk ideas that could accelerate progress to ending breast cancer. The PI must commit at least 50% of his/her full-time professional effort during the award period to breast cancer research.  
**Period of Support**: Up to 5 years  
**Funds/Direct Costs**: $5M direct costs for entire period of support  
**Program Contact**: Congressionally Directed Medical Research Program  
(301) 682-5507  
help@eBRAP.org

---

**Lung Cancer Research Foundation Research Grant on Disparities in Lung Cancer**  
**Deadline**: 4/1/2019  
[http://www.lungcancerresearchfoundation.org/research/funding-opportunities/lc-disparities-grant](http://www.lungcancerresearchfoundation.org/research/funding-opportunities/lc-disparities-grant)  
**About**: Lung cancer continues to be the number one cause of cancer deaths worldwide, accounting for an estimated 154,000 deaths annually in the United States alone. Additionally, with higher incidence rates and worse survival, lung cancer disproportionately affects various groups such as African Americans, Native Americans, low socioeconomic status populations and certain geographic locations. Despite progress to reduce the burden of tobacco, disparities in tobacco-related morbidity and mortality also remain. To help address these challenges, with support from the Stavros Niarchos Foundation in loving memory of Kathryn Louloudis, LCRF will support two research projects in 2019 with a focus on overcoming disparities in lung cancer.  
**Period of Support**: 2 years  
**Funds/Direct Costs**: $150,000 total costs for 2 years  
**Program Contact**: LCRF  
(212) 588-1902  
grants@lcrf.org

---

**American Cancer Society Research Scholar Grants**  
**Deadline**: 4/1/2019  
[https://www.cancer.org/research/we-fund-cancer-research/apply-research-grant/grant-types/research-scholar-grants.html](https://www.cancer.org/research/we-fund-cancer-research/apply-research-grant/grant-types/research-scholar-grants.html)  
**About**: The Research Scholar Grant (RSG) supports investigator-initiated projects across the cancer research continuum. Independent investigators in the first 6 years of an independent research career or faculty appointment are eligible to apply. Eligibility is extended for 8 years for clinician scientists who remain active in clinical care.  
**Period of Support**: Up to 4 years  
**Funds/Direct Costs**: Award are for up to $165,000 direct costs per year, plus 20% indirect costs  
**Program Contact**: grants@cancer.org

---

**St. Baldrick's Foundation Scholar (Career Development) Awards**  
**Deadline**: 3/29/2019  
[https://www.stbaldricks.org/file/Research/2019_St__Baldrick's_Foundation_Scholar_Career_Development_Awards.pdf](https://www.stbaldricks.org/file/Research/2019_St__Baldrick's_Foundation_Scholar_Career_Development_Awards.pdf)
**About:** The Scholar (Career Development) Award is meant to help develop the independent research of highly qualified individuals still early in their careers.  
**Period of Support:** 3 years  
**Funds/Direct Costs:** Up to $110,000 direct costs per year  
**Program Contact:** St. Baldrick’s Foundation  
(626) 792-8247  
grants@stbaldricks.org

---

**Intramural Funding Opportunities**

**Massey Cancer Center**  
**Multi-Investigator Award Program**  
**Pre-Application Deadline:** 3/1/2019  
**Full Application Deadline:** 4/1/2019  
https://massey.vcu.edu/research/funding/multi-investigator-award-program/  
**About:** The purpose of this funding is to provide preliminary support to either 1) a team of two or more investigators that are expected to lead to a multi-PI external peer-reviewed grant submission (e.g. NIH Multi-Investigator R01) or 2) two synergetic projects from a team of two or more investigators that are being developed to lead to the submission of a program project grant. This funding mechanism is intended to bring together investigators 1) who are authorities in their respective areas of research, 2) whose research is complimentary, and 3) where both investigators are essential for the success of the project.  
**Period of Support:** 1 year  
**Funds/Direct Costs:** Up to $100,000 per year  
**Internal Contact:** Morgan Hembarsky  
(804) 828-3114  
mhembarsky@vcu.edu

---

**Program Announcements (PA)**

**Multiple Institutes, including the National Cancer Institute**  
**Tobacco Use and HIV in Low and Middle Income Countries (R01 Clinical Trial Optional)**  
**Deadline:** 04/04/2019  
**About:** The purpose of this funding opportunity announcement (FOA) is to encourage research focused on tobacco use and human immunodeficiency virus (HIV) infection in low and middle income countries (LMICs). In particular, applications are encouraged that focus on the development and evaluation of tobacco cessation interventions tailored to HIV positive populations, including those with co-morbidities such as tuberculosis (TB), in low-resource settings in LMICs. This FOA provides funding for research planning, intervention delivery, and follow-up activities.  
**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** $275,000 direct costs for entire period of support  
**Program Contact:** Rebecca Ferrer  
(240) 276-5075  
ferrerra@mail.nih.gov

---

**NEW**  
**National Cancer Institute**  
**Administrative Supplements to NCI Grant and Cooperative Agreement Awards to Support Collaborations with the PDX Development and Trial Centers Research Network (PDXNet) [Admin Supp Clinical Trial Not Allowed]**  
**Deadline:** 3/28/2019  
**About:** This FOA supports supplemental funds to current NCI-funded research projects for new interdisciplinary collaborations between non-PDXNet investigators and PDXNet investigators to perform research within the scientific scope(s) of the parent grant and/or cooperative agreement award(s) that will lead to improved pre-clinical evaluations of novel therapeutic concepts using the large-scale PDX model collections of PDXNet, and that could ultimately be tested in NCI-sponsored clinical trials.  
**Period of Support:** 1 year  
**Funds/Direct Costs:** Application budgets are limited to no more than $80,000 in direct costs per year  
**Program Contact:** Jeffrey A. Moscow  
(240) 276-6565  
jeffrey.moscow@nih.gov

---

**National Cancer Institute**  
**Predicting Behavioral Responses to Population-Level Cancer Control Strategies (R21)**  
**Deadline:** 4/11/2019  
**About:** The goal of this funding opportunity announcement (FOA) is to facilitate research to identify individual influences on the effectiveness of population-level strategies that target cancer-related behaviors. We seek to encourage collaborations among scientists with expertise in health policy research and implementation, as well as investigators in scientific disciplines that have not traditionally conducted cancer or policy research.  
**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** $275,000 direct costs for entire period of support  
**Program Contact:** Rebecca Ferrer  
(240) 276-5075  
ferrerra@mail.nih.gov
Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R01)

**Deadline:** 4/11/2019


**About:** This Funding Opportunity Announcement (FOA) invites applications for intervention research designed to support caregivers of adult cancer patients. Interventions supported by this FOA are intended to provide caregivers with care training, promote coping skills, and ultimately help them manage care.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Michelle Mollica
(240) 276-7621
michelle.mollica@nih.gov

---

The NCI Transition Career Development Award (K22 Clinical Trial Required)

**Deadline:** 03/12/2019


**About:** This Funding Opportunity Announcement (FOA) supports an NCI program that facilitates the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions.

**Period of Support:** Up to 3 years

**Funds/Direct Costs:** Application budgets are composed of salary and other program-related expenses as described in announcement.

**Program Contact:** Sonia Jakowlew
(240) 276-5630
jakowles@mail.nih.gov

---

The NCI Transition Career Development Award (K22 Clinical Trial Not Allowed)

**Deadline:** 03/12/2019


**About:** This Funding Opportunity Announcement (FOA) supports an NCI program that facilitates the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions.

**Period of Support:** Up to 3 years

**Funds/Direct Costs:** Application budgets are composed of salary and other program-related expenses as described in announcement.

**Program Contact:** Sonia Jakowlew
(240) 276-5630
jakowles@mail.nih.gov

---

Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (R01 Clinical Trial Optional)

**Deadline:** 04/11/2019


**About:** The purpose of this Funding Opportunity Announcement (FOA) is to encourage projects to generate fundamental knowledge of affective processes. Basic affective science projects should have key consequences for single (e.g., cancer screening) and multiple (e.g., adherence to oral chemotherapy regimen) event decisions and behaviors across the cancer prevention and control continuum. The FOA is expected to encourage collaboration among cancer control researchers and those from scientific disciplines not traditionally connected to cancer control applications (e.g., affective and cognitive neuroscience, decision science, consumer science) to elucidate perplexing and understudied problems in affective and decision sciences with downstream implications for cancer prevention and control.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Rebecca Ferrer
(240) 276-5075
ferrera@mail.nih.gov

---

Modular R01s in Cancer Control and Population Sciences (R01)

**Deadline:** 03/06/2019


**About:** This funding opportunity announcement (FOA) encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, and implementation science.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** $250,000 direct costs per year

**Program Contact:** Scott Rogers
(240) 276-6932
rogerssc@mail.nih.gov
National Cancer Institute
Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (R21 Clinical Trial Optional)
Deadline: 4/11/2019
About: This Funding Opportunity Announcement (FOA) encourages transdisciplinary research that will leverage cognitive neuroscience to improve traditional measurement of cognitive impairment following cancer treatment, often referred to as "chemobrain." A better understanding of the acute- and late-term cognitive changes following exposure to adjuvant chemotherapy and molecularly-targeted treatments, including hormonal therapy, for non-central nervous system tumors can inform clinical assessment protocols with downstream implications for survivorship care plans.
Period of Support: Up to 2 years
Funds/Direct Costs: The combined budget for direct costs for the two-year project period may not exceed $275,000.
Program Contact: Jerry Suls
(240) 276-6811
jerry.suls@nih.gov

Multiple Institutes, including the National Cancer Institute
Mechanisms of Disparities in Etiology and Outcomes of Lung Cancer in the U.S.: The Role of Risk and Protective Factors (R21)
Deadline: 03/04/2019
About: This initiative will support exploratory and developmental multidisciplinary research to understand the underlying causal factors and mechanisms that result in lung cancer disparities in U.S. health disparity populations.
Period of Support: 2 years
Funds/Direct Costs: $275,000 direct costs for entire period of support
Program Contact: Anil Wali
(240) 276-6183
walia@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
Leveraging Health Information Technology (Health IT) to Address Minority Health and Health Disparities (R01 Clinical Trial Optional)
Deadline: 03/04/2019
About: This funding opportunity announcement (FOA) seeks to support research that examines how health information technology adoption impacts minority health and health disparity populations in access to care, quality of care, patient engagement, and health outcomes.
Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: April Oh
(240) 276-6709
April.oh@mail.nih.gov

Request for Applications (RFA)
National Cancer Institute
NCI Awardee Skills Development Consortium: Research Education Short Courses (UES Clinical Trial Not Allowed)
Deadline: 4/1/2019  

About: The overarching goal of this National Cancer Institute (NCI) UE5 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical cancer research needs.

Period of Support: Up to 3 years
Funds/Direct Costs: Application budgets are limited to $340,000 in direct costs per year.
Program Contact: Jeannette F. Korczak  
(240) 276-5630  
korczakj@mail.nih.gov

National Cancer Institute
NCI Awardee Skills Development Consortium: Program Logistics and Evaluation Coordinating Center (U24 Clinical Trial Not Allowed)
Deadline: 4/1/2019  

About: This U24 funding opportunity announcement (FOA) is a part of the National Cancer Institute (NCI) initiative to establish the "NCI Awardee Skills Development Consortium (NASDC)." The overarching goal of this initiative is to provide opportunities for current NCI grantees, especially those who are junior faculty (e.g., assistant professors, instructors, research scientists, or equivalent), to enhance their skills in areas that are critical for establishing and maintaining successful independent academic cancer research careers.

Period of Support: 3 years
Funds/Direct Costs: Application budgets are limited to $440,000 in direct costs per year.
Program Contact: Jeannette Korczak  
(240) 276-5630  
korczakj@mail.nih.gov

National Cancer Institute
Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21)
Deadline: 03/07/2019  

About: This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology.

Period of Support: Up to 3 years
Funds/Direct Costs: Direct costs are limited to $400,000 over a 3-year period, with no more than $200,000 in direct costs allowed in any single year.
Program Contact: Tony Dickherber  
(301) 547-9980  
dickherberaj@mail.nih.gov

National Cancer Institute
Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33)
Deadline: 03/07/2019  

About: This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research.

Period of Support: Up to 3 years
Funds/Direct Costs: Direct costs are limited to $300,000 per year.
Program Contact: Tony Dickherber  
(301) 547-9980  
dickherberaj@mail.nih.gov

National Cancer Institute
Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21)
Deadline: 03/07/2019  

About: This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens.

Period of Support: Up to 3 years
Funds/Direct Costs: Direct costs are limited to $400,000 over a 3-year period, with no more than $200,000 in direct costs allowed in any single year.
Program Contact: Tony Dickherber  
(301) 547-9980  
dickherberaj@mail.nih.gov
National Cancer Institute
Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33)
Deadline: 03/07/2019
About: This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens.
Period of Support: Up to 3 years
Funds/Direct Costs: Direct costs are limited to $300,000 per year.
Program Contact: Tony Dickherber (301) 547-9980 dickherberaj@mail.nih.gov

National Cancer Institute
Improving Outcomes for Pediatric, Adolescent and Young Adult Cancer Survivors (U01 Clinical Trial Required)
Deadline: 03/15/2019
About: Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) will stimulate the scientific development of effective, feasible, and scalable interventions to address adverse physical and psychosocial effects in survivors of pediatric and/or adolescent/young adult (AYA) cancers. These interventions may be delivered by providers, communities, and/or healthcare systems.
Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are limited to $500,000 in direct costs per year.
Program Contact: Sandra Mitchell (240) 276-6929 mitchlls@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
HEAL Initiative: Translational Development of Devices to Treat Pain (U18 Clinical Trial Not Allowed)
Deadline: 03/22/2019
About: The purpose of this Funding Opportunity Announcement (FOA) is to support preclinical development and demonstration of safe, effective, and non-addictive device-based technologies and approaches to treat pain. The goal of the program is to demonstrate treatment using credible neural targets for device-based interventions and/or diagnostics for pain, building upon the latest mechanistic knowledge about the anatomy and physiology of central, spinal, and peripheral pathways involved in pain.
Period of Support: Up to 3 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project. Budgets should rarely exceed $500,000 direct cost per year.
Program Contact: Diane St. Germain (240) 276-7082 dstgermain@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
Analytical and/or Clinical Validation of a Candidate Biomarker for Pain (R61/R33 Clinical Trial Optional)
Deadline: 03/07/2019
About: The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the validation of strong candidate biomarkers and endpoints for pain that can be used to facilitate the development of non-opioid pain therapeutics from discovery through Phase II clinical trials.
Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Ann O’Mara (301) 496-8541 omaraa@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
Optimization of Non-addictive Therapies [Small Molecules and Biologics] to Treat Pain (UG3/UH3)
Deadline: 03/06/2019
About: The purpose of this funding opportunity announcement (FOA) is to support preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain. The goal of the program is to accelerate the optimization and development of promising small molecule and biologic hits/leads towards clinical trials.
Period of Support: Up to 5 years
Funds/Direct Costs: The UG3 phase budget should not exceed $500k direct costs per year. The UH3 phase should not exceed $1.5M direct costs per year.
Program Contact: Amy Bartosch (240) 276-691 bartoschar@mail.nih.gov